Nektar Therapeutics
NKTR
Nektar Therapeutics (NKTR) news
Recent news
Nektar Therapeutics - Salt score ≤20 response maintained in 75% at 4 months, 63% at 6 months off treatment
AInvest Wire · Oct 1, 2026Nektar Therapeutics - 19% achieve salt score ≤10 at 6 months off treatment, up from 7% at 52 weeks
AInvest Wire · Oct 1, 2026Nektar Therapeutics - Phase 3 Zenith AA study to initiate in early 2027
AInvest Wire · Oct 1, 2026Nektar Therapeutics - Rezpegaldesleukin demonstrates durability and deepening of response through one year of treatment
AInvest Wire · Oct 1, 2026Nektar announces three oral presentations for Rezpegaldesleukin at the European Academy of Dermatology & Venereology (EADV) Congress 2026
AInvest Wire · Sep 28, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.